Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer | Zendy

Sebastian Michels | Zendy; Carina Heydt | Zendy; Bianca van Veggel | Zendy; Barbara Deschler-Baier | Zendy; Núria Pardo | Zendy; Kim Monkhorst | Zendy; Vanessa Rüsseler | Zendy; Jan A. Stratmann | Zendy; Frank Griesinger | Zendy; Susanne Steinhauser | Zendy; Anna Kostenko | Zendy; Joachim Diebold | Zendy; Jana Fassunke | Zendy; Rieke Fischer | Zendy; Walburga Engel-Riedel | Zendy; Oliver Gautschi | Zendy; Eva Geissinger | Zendy; Stefan Haneder | Zendy; Michaela A. Ihle | Zendy; HansGeorg Kopp | Zendy; Adrianus J. de Langen | Zendy; Alex MartínezMartí | Zendy; Lucia Nogová | Zendy; Thors﻿ten Persigehl | Zendy; Dennis Plenker | Zendy; Michael Puesken | Zendy; Ernst Rodermann | Zendy; Andreas Rosenwald | Zendy; Andreas H. Scheel | Zendy; Matthias Scheffler | Zendy; Werner Spengler | Zendy; Ruth SeggewissBernhardt | Zendy; Johannes Brägelmann | Zendy; Martin Sebastian | Zendy; Bart Vrugt | Zendy; Martin Hellmich | Zendy; Martin L. Sos | Zendy; Lukas C. Heukamp | Zendy; Enriqueta Felip | Zendy; Sabine MerkelbachBruse | Zendy; Egbert F. Smit | Zendy; Reinhard Büttner | Zendy; Jürgen Wolf | Zendy

Open Access

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

Author(s) -

Sebastian Michels,

Carina Heydt,

Bianca van Veggel,

Barbara Deschler-Baier,

Núria Pardo,

Kim Monkhorst,

Vanessa Rüsseler,

Jan A. Stratmann,

Frank Griesinger,

Susanne Steinhauser,

Anna Kostenko,

Joachim Diebold,

Jana Fassunke,

Rieke Fischer,

Walburga Engel-Riedel,

Oliver Gautschi,

Eva Geissinger,

Stefan Haneder,

Michaela A. Ihle,

HansGeorg Kopp,

Adrianus J. de Langen,

Alex MartínezMartí,

Lucia Nogová,

Thorsten Persigehl,

Dennis Plenker,

Michael Puesken,

Ernst Rodermann,

Andreas Rosenwald,

Andreas H. Scheel,

Matthias Scheffler,

Werner Spengler,

Ruth SeggewissBernhardt,

Johannes Brägelmann,

Martin Sebastian,

Bart Vrugt,

Martin Hellmich,

Martin L. Sos,

Lukas C. Heukamp,

Enriqueta Felip,

Sabine MerkelbachBruse,

Egbert F. Smit,

Reinhard Büttner,

Jürgen Wolf

Publication year - 2019

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.18.00210

Subject(s) - lung cancer , epidermal growth factor receptor , tyrosine kinase inhibitor , cancer research , tyrosine kinase , growth factor receptor , receptor tyrosine kinase , biology , receptor , medicine , oncology , cancer

Third-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are effective in acquired resistance (AR) to early-generation EGFR TKIs in EGFR-mutant lung cancer. However, efficacy is marked by interindividual heterogeneity. We present the molecular profiles of pretreatment and post-treatment samples from patients treated with third-generation EGFR TKIs and their impact on treatment outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research